Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMC-RST: Roommate Screening and Treatment to Boost SMC
NCT04816461Phase 4Completed
- Sponsor
- Institut de Recherche en Sciences de la Santé
- Start
- Jul 2021
- Primary completion
- Jun 2023
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dihydroartemisinin + piperaquine in malaria, sponsored by Institut de Recherche en Sciences de la Santé. Primary endpoint: Incidence of uncomplicated malaria at 1 year. Started Jul 2021; status: completed.
02
Drugs
dihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04816461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04816461.